Autologous peripheral blood progenitor cell transplantation.
Autologous peripheral blood progenitor cell transplantation.
复制标题
自体外周血祖细胞移植。
DOI：
10.1002/jca.2920100307
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Anderson,KC
中科院分区：
文献类型：
--
作者：
Anderson,KC
当患者接受重组生长因子，即粒细胞（G）或粒细胞巨噬细胞（GM）集落刺激因子（CSF）时，在化疗反弹时使用目前可用的高效单采技术，可以促进自体外周血干细胞（PBSC）的收获。理想情况下，应在患者出现大量干细胞毒素（即烷化剂或亚硝基脲）之前进行血浆分离术。这一策略促进了实体瘤或血液恶性肿瘤患者以单一治疗方案或分次剂量的高剂量放化疗的使用，并且比骨髓移植（BMT）更快地植入。尽管没有测量再生干细胞的测定，但 PBSC 内 CD34+ 细胞的计数是一种直接而快速的测定，可提供早期和晚期长期重建能力的指数，因为它与集落形成单位 (CFU)-GM、以及前祖细胞或 delta 测定和长期培养起始细胞 (LTC-IC) 相关。据报道，植入需要≥2×106CD34+细胞/kg受体体重的阈值，但可能根据临床环境而变化。在血液恶性肿瘤和实体瘤的情况下，动员正常 PBSC 的策略也会增加 PB 内的肿瘤细胞污染，但这些肿瘤细胞对患者预后的意义尚不清楚。最近，使用磁珠或柱或刚性板上的免疫吸附从 PBSC 中分离 CD34+ 细胞，以富集正常造血祖细胞并可能减少肿瘤细胞污染。至于其他细胞血液成分，已经制定了标准，以确保有效的收集和处理、解冻和回输，并保持最佳的 PBPC 活力。最后，未来的临床研究方向包括造血祖细胞的离体扩增；使用脐带或胎盘作为祖细胞的丰富来源；同基因造血干细胞移植；相关和非相关的同种异体造血干细胞移植；使用供体 PBSC 输注治疗感染（即 Epstein Barr 病毒）或同种异体 BMT 后肿瘤复发；和基因治疗方法。
Harvesting of autologous peripheral blood stem cells (PBSCs) has been facilitated by using currently available, efficient apheresis technology at the time of rebound from chemotherapy while patients are receiving recombinant growth factors, i.e., granulocyte (G) or granulocyte‐macrophage (GM) colony stimulating factor (CSF). Ideally pheresis should be done before patients have had extensive stem cell toxins, i.e., alkylating agents or nitrosoureas. This strategy has facilitated the use of high dose chemoradiotherapy given as a single regimen or in a divided dose for patients with solid tumors or hematologic malignancies and results in more rapid engraftment than bone marrow transplantation (BMT). Although mere are no assays which measure repopulating stem cells, enumeration of CD34+cells within PBSCs is a direct and rapid assay which provides an index of both early and late long‐term reconstitutive capacity, since it correlates with colony‐forming unit (CFU)‐GMs, as well as pre‐progenitor or delta assays and long‐term culture‐initiating cells (LTC‐IC). A threshold of ≥2 × 106CD34+cells/kg recipient body weight has been reported to be required for engraftment, but may vary depending upon the clinical setting. Strategies for mobilization of normal PBSCs also increase tumor cell contamination within PB in the setting of both hematologic malignancies and solid tumors, but the significance of these tumor cells in terms of patient outcome is unclear. Recently isolation of CD34+cells from PBSCs has been done using magnetic beads or immunoabsorption on columns or rigid plates in order to enrich for normal hematopoietic progenitors and potentially decrease tumor cell contamination. As for other cellular blood components, standards have been developed to assure efficient collection and processing, thawing, and reinfusion, and to maintain optimal PBPC viability. Finally, future directions of clinical research include expansion of hematopoietic progenitor cells ex vivo; use of umbilical cord or placenta as rich sources of progenitor cells; syngeneic hematopoietic stem cell transplantation; related and unrelated allogeneic hematopoietic stem cell transplantation; treatment of infections, i.e., Epstein Barr virus, or tumor relapse after allogeneic BMT using donor PBSC infusions; and gene therapy approaches.
登录
查看更多内容
噻替派、白消安和环磷酰胺：高危多发性骨髓瘤自体骨髓或造血干细胞移植的新准备方案。
影响因子：
20.3
作者：
M. Dimopoulos;R. Alexanian;D. Przepiorka;J. Hester;B. Andersson;S. Giralt;R. Mehra;K. V. Besien;K. Delasalle;C. Reading
通讯作者：
C. Reading
影响因子：
20.3
作者：
G. Tricot;S. Jagannath;D. Vesole;J. Nelson;S. Tindle;L. Miller;B. Cheson;J. Crowley;B. Barlogie
通讯作者：
G. Tricot;S. Jagannath;D. Vesole;J. Nelson;S. Tindle;L. Miller;B. Cheson;J. Crowley;B. Barlogie
高剂量放化疗和自体造血干细胞移植治疗多发性骨髓瘤：一项涉及 63 名患者的 II 期试验结果。
影响因子：
20.3
作者：
J. Fermand;S. Chevret;Ph. Ravaud;M. Diviné;Véronique Leblond;Francois Dreyfus;Xavier Mariette;J. Brouet
通讯作者：
J. Brouet
晚期多发性骨髓瘤患者大剂量化疗后 CD34+ 外周血祖细胞移植。
影响因子：
20.3
作者：
G. Schiller;R. Vescio;C. Freytes;G. Spitzer;F. Sahebi;Myung Lee;Chunjiao Wu;Jing Cao;J. C. Lee;Charlie;Hong;A. Lichtenstein;M. Lill;Jeff M. Hall;R. Berenson;J. Berenson
通讯作者：
J. Berenson
在高剂量 VP16、异环磷酰胺、卡铂和表柔比星后，阳性选择的自体血 CD34+ 细胞和未分离的外周血祖细胞介导相同的造血植入。
影响因子：
20.3
作者：
W. Brugger;R. Henschler;S. Heimfeld;R. Berenson;R. Mertelsmann;Lothar Kanz
通讯作者：
Lothar Kanz